Alnylam Pharmaceuticals (ALNY)

$463.43 -0.57 (-0.12%)
Market Cap 60.82B
Revenue (ttm) 2.25B
Net Income (ttm) -278.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 394.29
Profit Margin -12.37%
Debt to Equity Ratio 0.00
Volume 771,300
Avg Vol 1,085,448
Day's Range N/A - N/A
Shares Out 131.08M
Stochastic %K 17%
Beta 0.36
Analysts Strong Sell
Price Target $483.00

Company Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 551 8200
Fax: 617 551 8101
Address:
675 West Kendall Street, Henri A. Termeer Square, Cambridge, United States
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:05 PM
$ALKT $ALL $ALLY $ALMU $ALNY 🔥 Cycle Trading Signal plugged into AI 🔥 list 10/10 to 10/24 results
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 3:16 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ALNY Current Share Price: $464.08 Contracts: $ALNY January 15, 2027 $470 Calls Scale in: $90.82- $111.00 Scale out: $141.27-$181.64 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
smartkarma
smartkarma Oct. 24 at 1:34 AM
$ALNY | Nasdaq100 Dec2025 Forecast (Part 2): ALNY at the Top; GFS at the Bottom; Spinoffs Pending "ALNY leads additions while GFS tops deletions for December 2025. VSNT and SOLS are expected to be removed within days of their respective spinoffs, beginning with SOLS on 30 October." - Dimitris Ioannidis (ORTEX) Read more: https://www.smartkarma.com/insights/nasdaq100-dec2025-forecast-part-2-alny-at-the-top-gfs-at-the-bottom-spinoffs-pending
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 23 at 6:11 PM
$ALLY $ALMU $ALNY
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 23 at 3:54 AM
Enter: $ALNY NOV 21 2025 $470 CALLS Buy in Price: $25.65 - $26.40 Take Profit: $36.68 Stop Bleeding: $22.57 ROI Potential: 43% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 22 at 5:51 PM
$ALNY Share Price: $462.18 Contract Selected: Mar 20, 2026 $460 Calls Buy Zone: $47.26 – $58.38 Target Zone: $79.36 – $96.99 Potential Upside: 59% ROI Time to Expiration: 148 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 22 at 3:07 AM
Enter: $ALNY NOV 21 2025 $480 CALLS Buy in Price: $25.70 - $27.40 Take Profit: $51.91 Stop Bleeding: $22.62 ROI Potential: 102% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 20 at 1:35 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ALNY Current Share Price: $481.67 Contracts: $ALNY January 15, 2027 $500 Calls Scale in: $73.71- $90.09 Scale out: $114.66-$147.42 Can Easily Capture: 60% ROI Blended DTE: 453 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 1:27 AM
Enter: $ALNY NOV 21 2025 $490 CALLS Buy in Price: $26.96 - $28.80 Take Profit: $48.80 Stop Bleeding: $23.72 ROI Potential: 81% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 19 at 12:23 AM
Enter: $ALNY NOV 21 2025 $490 CALLS Buy in Price: $26.96 - $28.80 Take Profit: $51.76 Stop Bleeding: $23.72 ROI Potential: 92% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
Latest News on ALNY
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

Oct 16, 2025, 8:00 AM EDT - 8 days ago

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Oct 11, 2025, 8:02 AM EDT - 13 days ago

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

AEM EQIX PLD PSTG

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

Oct 1, 2025, 7:30 AM EDT - 24 days ago

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

Sep 28, 2025, 11:13 AM EDT - 26 days ago

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Sep 23, 2025, 2:23 PM EDT - 4 weeks ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

Sep 18, 2025, 9:15 AM EDT - 5 weeks ago

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

ILMN

Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 5:01 PM EDT - 6 weeks ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

Sep 9, 2025, 11:16 PM EDT - 6 weeks ago

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes

Sep 8, 2025, 4:15 PM EDT - 6 weeks ago

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes

Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript

Sep 3, 2025, 4:58 PM EDT - 7 weeks ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript

Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives

Sep 3, 2025, 12:56 AM EDT - 7 weeks ago

Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM

Aug 31, 2025, 5:15 AM EDT - 7 weeks ago

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

Aug 30, 2025, 10:30 AM EDT - 7 weeks ago

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

Aug 30, 2025, 10:30 AM EDT - 7 weeks ago

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 2 months ago

mRNA Biotechs - Long-Term Value Risks Abound

BNTX DHR GRAL ILMN IONS MRNA RGEN

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Aug 27, 2025, 8:00 AM EDT - 2 months ago

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Scenic Enters License and Research Agreement with Alnylam

Aug 26, 2025, 5:00 AM EDT - 2 months ago

Scenic Enters License and Research Agreement with Alnylam

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

Aug 11, 2025, 8:00 AM EDT - 2 months ago

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

Aug 5, 2025, 8:00 AM EDT - 2 months ago

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

Aug 1, 2025, 2:28 PM EDT - 3 months ago

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 3 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT AMGN ARGX AZN BAX BIIB

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 3 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT AMGN ARGX AZN BAX BIIB

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:47 PM EDT - 3 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

Jul 31, 2025, 3:36 PM EDT - 3 months ago

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

Alnylam: Amvuttra Is Just Getting Started

Jul 31, 2025, 3:13 PM EDT - 3 months ago

Alnylam: Amvuttra Is Just Getting Started

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

Jul 31, 2025, 8:00 AM EDT - 3 months ago

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

Five years after COVID, pharma shares languish in US policy limbo

Jul 23, 2025, 9:57 AM EDT - 3 months ago

Five years after COVID, pharma shares languish in US policy limbo

ABBV ABT AZN EW LLY MRK NVO

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

Jul 17, 2025, 8:00 AM EDT - 3 months ago

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

Jul 1, 2025, 9:06 AM EDT - 4 months ago

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

Alnylam Pharmaceuticals Names Garg R&D Chief

Jun 18, 2025, 12:04 PM EDT - 4 months ago

Alnylam Pharmaceuticals Names Garg R&D Chief

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

Jun 18, 2025, 10:05 AM EDT - 4 months ago

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Jun 9, 2025, 6:00 AM EDT - 4 months ago

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 5 months ago

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

Alnylam Issues 2024 Corporate Responsibility Report

May 20, 2025, 9:00 AM EDT - 5 months ago

Alnylam Issues 2024 Corporate Responsibility Report

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

May 17, 2025, 5:50 AM EDT - 5 months ago

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

May 12, 2025, 7:00 AM EDT - 5 months ago

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

May 5, 2025, 10:00 AM EDT - 6 months ago

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript

May 1, 2025, 1:11 PM EDT - 6 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

May 1, 2025, 8:00 AM EDT - 6 months ago

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Apr 28, 2025, 8:00 AM EDT - 6 months ago

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

Apr 17, 2025, 8:00 AM EDT - 6 months ago

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 7 months ago

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

Mar 31, 2025, 2:05 PM EDT - 7 months ago

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

XBI RYTM VRTX XENE

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025

Mar 29, 2025, 1:00 PM EDT - 7 months ago

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

Mar 28, 2025, 4:44 PM EDT - 7 months ago

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials

Mar 28, 2025, 7:14 AM EDT - 7 months ago

siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials

Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock

Mar 24, 2025, 2:08 PM EDT - 7 months ago

Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock

Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster

Mar 21, 2025, 5:37 PM EDT - 7 months ago

Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster

Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps

Mar 21, 2025, 10:00 AM EDT - 7 months ago

Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps

Alnylam shares rise on expanded heart drug approval

Mar 21, 2025, 7:34 AM EDT - 7 months ago

Alnylam shares rise on expanded heart drug approval

BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:05 PM
$ALKT $ALL $ALLY $ALMU $ALNY 🔥 Cycle Trading Signal plugged into AI 🔥 list 10/10 to 10/24 results
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 3:16 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ALNY Current Share Price: $464.08 Contracts: $ALNY January 15, 2027 $470 Calls Scale in: $90.82- $111.00 Scale out: $141.27-$181.64 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
smartkarma
smartkarma Oct. 24 at 1:34 AM
$ALNY | Nasdaq100 Dec2025 Forecast (Part 2): ALNY at the Top; GFS at the Bottom; Spinoffs Pending "ALNY leads additions while GFS tops deletions for December 2025. VSNT and SOLS are expected to be removed within days of their respective spinoffs, beginning with SOLS on 30 October." - Dimitris Ioannidis (ORTEX) Read more: https://www.smartkarma.com/insights/nasdaq100-dec2025-forecast-part-2-alny-at-the-top-gfs-at-the-bottom-spinoffs-pending
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 23 at 6:11 PM
$ALLY $ALMU $ALNY
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 23 at 3:54 AM
Enter: $ALNY NOV 21 2025 $470 CALLS Buy in Price: $25.65 - $26.40 Take Profit: $36.68 Stop Bleeding: $22.57 ROI Potential: 43% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 22 at 5:51 PM
$ALNY Share Price: $462.18 Contract Selected: Mar 20, 2026 $460 Calls Buy Zone: $47.26 – $58.38 Target Zone: $79.36 – $96.99 Potential Upside: 59% ROI Time to Expiration: 148 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 22 at 3:07 AM
Enter: $ALNY NOV 21 2025 $480 CALLS Buy in Price: $25.70 - $27.40 Take Profit: $51.91 Stop Bleeding: $22.62 ROI Potential: 102% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 20 at 1:35 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ALNY Current Share Price: $481.67 Contracts: $ALNY January 15, 2027 $500 Calls Scale in: $73.71- $90.09 Scale out: $114.66-$147.42 Can Easily Capture: 60% ROI Blended DTE: 453 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 1:27 AM
Enter: $ALNY NOV 21 2025 $490 CALLS Buy in Price: $26.96 - $28.80 Take Profit: $48.80 Stop Bleeding: $23.72 ROI Potential: 81% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 19 at 12:23 AM
Enter: $ALNY NOV 21 2025 $490 CALLS Buy in Price: $26.96 - $28.80 Take Profit: $51.76 Stop Bleeding: $23.72 ROI Potential: 92% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 18 at 4:50 AM
Enter: $ALNY NOV 21 2025 $490 CALLS Buy in Price: $26.96 - $31.30 Take Profit: $64.43 Stop Bleeding: $23.72 ROI Potential: 139% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 18 at 4:30 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ALNY Current Share Price: $481.07 Contracts: $ALNY January 15, 2027 $500 Calls Scale in: $73.71- $90.09 Scale out: $114.66-$147.42 Can Easily Capture: 60% ROI Blended DTE: 455 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 1:47 PM
Truist Securities updates rating for Alnylam Pharmaceuticals ( $ALNY ) to Buy, target set at 459 → 535.
1 · Reply
StockConsultant
StockConsultant Oct. 17 at 1:25 PM
$ALNY Alnylam Pharmaceuticals stock, narrow range breakout
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 16 at 10:03 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ALNY Current Share Price: $470.27 Contracts: $ALNY January 15, 2027 $480 Calls Scale in: $76.59- $93.60 Scale out: $119.13-$153.17 Can Easily Capture: 60% ROI Blended DTE: 456 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
IsabellaDC
IsabellaDC Oct. 16 at 2:44 PM
Stocks that are at an all-time high: $MPWR $FN $ALNY $MU $GRAL and so on...
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 16 at 12:39 PM
Enter: $ALNY NOV 21 2025 $480 CALLS Buy in Price: $28.40 - $28.85 Take Profit: $57.99 Stop Bleeding: $25.39 ROI Potential: 101% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
Varlamovnyse
Varlamovnyse Oct. 15 at 9:24 AM
$ALNY
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 15 at 6:30 AM
Enter: $ALNY NOV 21 2025 $470 CALLS Buy in Price: $32.10 - $35.72 Take Profit: $52.87 Stop Bleeding: $31.43 ROI Potential: 48% Exit Within: 1 Weeks https://moneygroup.us/alerts
0 · Reply
johnnygogogo
johnnygogogo Oct. 14 at 3:17 PM
$ALNY it’s a $475 vs. $473 Morgan sandwich. Double Morgan, hold the onions! @skeezbag
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 14 at 7:07 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ALNY Current Share Price: $460.46 Contracts: $ALNY January 15, 2027 $470 Calls Scale in: $47.05- $57.50 Scale out: $73.18-$94.09 Can Easily Capture: 60% ROI Blended DTE: 459 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 14 at 6:40 AM
Enter: $ALNY NOV 21 2025 $470 CALLS Buy in Price: $29.80 - $31.00 Take Profit: $69.75 Stop Bleeding: $27.28 ROI Potential: 125% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply